BridgeBio Oncology Therapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
PIPE
- (Announced)
- Latest Deal Amount
-
$260M
- Investors
-
7
BridgeBio Oncology Therapeutics General Information
Description
Developer of oncology therapeutics designed to target RAS-dependent cancers. The company utilizes a deep understanding of RAS signaling biology to create drugs capable of selectively inhibiting RAS-driven PI3K activation and a broad range of KRAS mutants, enabling patients to benefit from precision treatments addressing both active and inactive cancer-driving states.
Contact Information
Website
www.bridgebiooncology.comCorporate Office
- 1 Corporate Drive
- South San Francisco, CA 94080
- United States
Corporate Office
- 1 Corporate Drive
- South San Francisco, CA 94080
- United States
BridgeBio Oncology Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. PIPE | 28-Feb-2025 | $260M | Announced | Clinical Trials - Phase 1 | ||
| 3. Reverse Merger | 28-Feb-2025 | Announced | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC | 30-Apr-2024 | $200M | $200M | Completed | Clinical Trials - Phase 1 | |
| 1. Spin-Off | 01-Aug-2016 | Completed | Clinical Trials - Phase 1 |
BridgeBio Oncology Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BridgeBio Oncology Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BridgeBio Oncology Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | ||
| Casdin Capital | Venture Capital | Minority | ||
| Cormorant Capital | Real Estate | Minority | ||
| EcoR1 Capital | Venture Capital | Minority | ||
| GV | Corporate Venture Capital | Minority |
BridgeBio Oncology Therapeutics Acquisitions (1)
BridgeBio Oncology Therapeutics’s most recent deal was a Merger/Acquisition with Helix Acquisition (Special Purpose Acquisition Company). The deal was made on 28-Feb-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Helix Acquisition (Special Purpose Acquisition Company) | 28-Feb-2025 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
BridgeBio Oncology Therapeutics FAQs
-
When was BridgeBio Oncology Therapeutics founded?
BridgeBio Oncology Therapeutics was founded in 2016.
-
Where is BridgeBio Oncology Therapeutics headquartered?
BridgeBio Oncology Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of BridgeBio Oncology Therapeutics?
BridgeBio Oncology Therapeutics has 50 total employees.
-
What industry is BridgeBio Oncology Therapeutics in?
BridgeBio Oncology Therapeutics’s primary industry is Drug Discovery.
-
Is BridgeBio Oncology Therapeutics a private or public company?
BridgeBio Oncology Therapeutics is a Private company.
-
What is BridgeBio Oncology Therapeutics’s current revenue?
The current revenue for BridgeBio Oncology Therapeutics is .
-
How much funding has BridgeBio Oncology Therapeutics raised over time?
BridgeBio Oncology Therapeutics has raised $460M.
-
Who are BridgeBio Oncology Therapeutics’s investors?
Aisling Capital, Casdin Capital, Cormorant Capital, EcoR1 Capital, and GV are 5 of 7 investors who have invested in BridgeBio Oncology Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
